Clinical Trials Directory

Trials / Completed

CompletedNCT03485144

A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan

A Phase II Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Immunogenicity and Safety of TetraVax-DV in Healthy Adults in Taiwan

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
54 (actual)
Sponsor
Medigen Vaccine Biologics Corp. · Industry
Sex
All
Age
20 Years – 70 Years
Healthy volunteers
Accepted

Summary

The goal of this study is to determine the immunogenicity and safety of TV003(TetraVax-DV), a live attenuated tetravalent dengue vaccine candidate, in healthy human subjects in Taiwan

Conditions

Interventions

TypeNameDescription
BIOLOGICALTV003Live attenuated virus vaccine-TetraVax-DV
BIOLOGICALPlacebo for TV003Placebo

Timeline

Start date
2017-12-12
Primary completion
2019-05-10
Completion
2019-05-10
First posted
2018-04-02
Last updated
2019-08-14

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT03485144. Inclusion in this directory is not an endorsement.

A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan (NCT03485144) · Clinical Trials Directory